Skip to main content
رجوع
ANIP logo

ANI Pharmaceuticals, Inc.

جودة البيانات: 100%
ANIP
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 73.31
▼ KWD 0.61 (-0.83%)
القيمة السوقية: 1.65B
نطاق اليوم
KWD 72.92 KWD 74.43
نطاق 52 أسبوعًا
KWD 56.71 KWD 99.50
حجم التداول
216,023
متوسط 50 يوم / 200 يوم
KWD 78.57 / KWD 80.76
الإغلاق السابق
KWD 73.92

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 21.0 0.3
P/B 3.0 2.9
ROE % 16.2 3.7
Net Margin % 8.9 3.8
Rev Growth 5Y % 42.2 10.0
D/E 0.6 0.2

السعر المستهدف للمحللين

Hold
KWD 107.000 +46.0%
Low: KWD 90.000 High: KWD 124.000
مكرر الربحية المستقبلي
8.2
ربحية السهم المستقبلية
KWD 9.054
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
1.1 B

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 13.447
KWD 12.712 – KWD 13.946
1.5 B 2
FY2029 KWD 12.688
KWD 11.994 – KWD 13.158
1.4 B 2
FY2028 KWD 12.458
KWD 11.778 – KWD 12.921
1.3 B 3

النقاط الرئيسية

Revenue grew 42.18% annually over 5 years — strong growth
ROE of 16.16% — decent returns on equity
Generating 171.39M in free cash flow
Cash machine — converts 218.79% of earnings into free cash flow
Capital efficient — spends only 1.57% of revenue on capex

النمو

Revenue Growth (5Y)
42.18%
Revenue (1Y)43.78%
Earnings (1Y)N/A
FCF Growth (3Y)30.62%

الجودة

Return on Equity
16.16%
ROIC7.04%
Net Margin8.87%
Op. Margin9.20%

الأمان

Debt / Equity
0.60
Current Ratio2.71
Interest Coverage4.05

التقييم

P/E Ratio
21.02
P/B Ratio3.04
EV/EBITDA20.76
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 43.78% Revenue Growth (3Y) 34.71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 104.24%
Revenue Growth (5Y) 42.18% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 883.37M Net Income (TTM) 78.34M
ROE 16.16% ROA 5.44%
Gross Margin 51.01% Operating Margin 9.20%
Net Margin 8.87% Free Cash Flow (TTM) 171.39M
ROIC 7.04% FCF Growth (3Y) 30.62%
Safety
Debt / Equity 0.60 Current Ratio 2.71
Interest Coverage 4.05 Dividend Yield 0.00%
Valuation
P/E Ratio 21.02 P/B Ratio 3.04
P/S Ratio 1.86 PEG Ratio -0.05
EV/EBITDA 20.76 Dividend Yield 0.00%
Market Cap 1.65B Enterprise Value 1.69B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 883.37M 614.38M 486.82M 316.39M 216.14M
Net Income 78.34M -18.52M 18.78M -47.90M -42.60M
EPS (Diluted) 3.32 -1.04 0.94 -3.05 -3.40
Gross Profit 450.64M 364.17M 305.30M 177.60M 115.53M
Operating Income 81.23M 584,000.0 46.97M -35.28M -39.79M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.44B 1.28B 904.42M 760.09M 771.60M
Total Liabilities 899.65M 855.17M 446.82M 421.55M 412.86M
Shareholders' Equity 540.72M 428.53M 457.60M 338.54M 358.74M
Total Debt 325.20M 624.09M 285.67M 286.52M 287.37M
Cash & Equivalents 285.59M 144.86M 221.12M 48.23M 100.30M
Current Assets 753.12M 527.68M 519.82M 344.26M 321.78M
Current Liabilities 278.11M 193.68M 145.48M 99.44M 87.54M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#124 of 1052
67

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026